Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
Update: Value-Based Pricing in the UK
11 January 2011
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For…
Is the Aim of the Health Care System to Maximise QALYs? An Investigation of
1 May 2011
The appraisal of health care technologies by the UK’s National Institute for Health and Clinical Excellent (NICE) focuses on cost effectiveness, usually measured in terms of…
Measuring Value: OHE at ISPOR
4 January 2011
Members of the OHE team participated in a number of sessions at ISPOR’s 13th Annual European Congress in November. This post summarizes the contributions of Prof…
Incorporating Multiple Criteria in HTA: Methods and Processes
1 March 2011
What a health care system should pay for depends, of course, on the health gain that results. Health technology assessment (HTA) and cost-effectiveness analysis have become…
The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
1 January 2011
This report examines and makes suggestions for the appropriate use of health technology assessment (HTA) in emerging markets. In particulary, it considers how the stage of development…
Australia’s Publicly Funded Vaccines Market
1 December 2010
The OHE recently published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by the…
The UK’s Publicly Funded Vaccines Market
23 November 2010
The OHE has just published reports on the vaccines markets in Australia and in the UK, originally prepared as case studies for a project funded by…
Access to Orphan Drugs in the EU
21 October 2010
Legislation in the EU provides incentives for the developmeng of drugs for rare diseases, known as orphan medicinal products (OMPs). At a recent conference, OHE’s Dr…
Which English Hospital is Best at Hips?
29 September 2010
Earlier this month, the first set of data on post operative patient reported outcomes (PROMs) was published by the Department of Health (DH). For the first…